+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Neurology Edition: The Views of 231 Neurology Patient Groups

  • ID: 5184587
  • Report
  • October 2020
  • Region: Global
  • 50 Pages
  • PatientView
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Eli Lilly
  • Lundbeck
  • Novartis
  • Sandoz
  • MORE

This is the 7th edition of ‘The Corporate Reputation of Pharma - from the Perspective of neurology Patient Groups’. These 2019 results are drawn from a survey of neurology patient groups, conducted November 2019 - February 2020.

About the 2019 survey of neurology patient groups

  • Country headquarters. Respondent neurology patient groups came from 47 countries.
  • Geographic remit. 54% had a national geographic remit; 26% were regional (an area within one country); 12% were local, and 7% had an international remit.

The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Neurology Edition

On the relationships that neurology patient groups had with pharma, 2019

  • 54% of the 231 neurology patient groups responding to the 2019 survey worked with at least one pharma company. The 21 companies included for assessment in the 2019 neurology ‘Corporate-Reputation’ analyses (in alphabetical order): AbbVie, Allergan, Almirall, Bayer, Biogen, Eisai, Eli Lilly, Grünenthal,  Ipsen, Lundbeck, Merck & Co/MSD, Merck KGaA/EMD Serono, Novartis,  Pfizer, Roche/Genentech, Sandoz, Sanofi, Servier, Takeda/Shire, Teva and UCB.

Many pharmaceutical companies have withdrawn from the field of neuroscience during the past two decades - mostly because of a series of clinical failures [Jacob Bell, ‘Big Pharma Backed Away from Brain Drugs. Is a Return in Sight?’, Biopharmadive, January 29th 2020]. This decline is reflected in the numbers of companies examined in the neurology analyses (only 21 companies qualified for inclusion in 2019, against 30 in 2018).

What this report contains

Industry-wide analyses: The 2019 neurology ‘Corporate-Reputation’ report examines issues of importance to neurology patient groups, including three subjects that dominated the neurology patient-group/pharma landscape in 2019 ...

  • pharma’s ability to innovate, and to provide high-quality drugs of benefit to neurology patients;
  • shortages of neurology drugs;
  • equitable access to neurology drugs; and
  • patient engagement in neurology R&D.

Analyses are reinforced by extensive feedback from 2019’s respondent neurology patient groups [found in Appendix I of the report], organised according to the countries of the respondent patient groups.

Key industry-wide findings for neurology, 2019

The corporate reputation of the pharma industry as a whole, according to patient groups specialising in neurological conditions 2019’s respondent neurology patient groups held diverse opinions about the pharmaceutical industry (depending on the neurological specialty of the organisation). While 50% of 2019’s 43 respondent multiple sclerosis patient groups thought that the pharma industry had an “Excellent” or “Good” corporate reputation, only 26% of 2019’s 23 respondents Parkinson’s patient groups said the same [see chart below].

The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Neurology Edition

Disparate views were also expressed by neurology patient groups when scoring the industry for its ability to carry out activities of importance to neurology patients. Again, multiple-sclerosis patient groups were the most positive about pharma’s ability to innovate, and to provide high-quality products (well over half of 2019’s 43 respondent MS patient groups rated the industry “Excellent” or “Good” at these two activities). 30% or less of 2019’s 23 respondent Parkinson’s patient groups expressed the same opinion.

Key company findings for neurology, 2019

Individual company analyses: The 21 pharma companies are reviewed by 2019’s 231 respondent neurology patient groups for their overall corporate reputation, and for performance at 12 individual indicators of corporate reputation.

Roche/Genentech was ranked overall 1st out of 21 companies for corporate reputation in 2019 by the 124 respondent neurology patient groups familiar with the company (in 2018, Roche had been ranked overall 5th out of 30 companies by the neurology patient groups familiar with it). 2019’s 46 respondent neurology patient groups that partnered with Roche also ranked the company overall 1st out of 14 companies (in 2018, Roche had been ranked overall 4th out of 18 companies by its neurology patient group partners).

Novartis was ranked overall 2nd out of 21 companies for corporate reputation in 2019 by the 152 respondent neurology patient groups familiar with the company (in 2018, Novartis had also been ranked overall 2nd out of 30 companies by the neurology patient groups familiar with it). Novartis’ 66 respondent neurology patient-group partners ranked the company overall 4th out of 14 companies for corporate reputation in 2019 (in 2018, Novartis had been ranked overall 8th out of 18 companies by its neurology patient group partners).

Biogen was ranked overall 3rd out of 21 companies for corporate reputation in 2019 by the 94 respondent neurology patient groups familiar with the company (in 2018, Biogen had been ranked overall 4th out of 30 companies by the neurology patient groups familiar with it). 2019’s 40 respondent neurology patient groups that stated they partnered with Biogen also ranked the company overall 3rd out of 14 companies (in 2018, Biogen had been ranked overall 7th out of 18 companies by its neurology patient-group partners).

Other success stories in 2019’s neurology results

Epilepsy: UCB was ranked 1st out of 5 companies for corporate reputation in 2019 by the 26 respondent epilepsy patient groups familiar with the company (in 2018, UCB had also been ranked overall 1st out of 6 companies for corporate reputation that year by epilepsy patient groups familiar with it).

Multiple sclerosis: Sanofi was ranked 1st out of 7 companies for corporate reputation in 2019 by the 33 respondent multiple-sclerosis patient groups familiar with it (in 2018, Sanofi had also been ranked overall 1st out of 8 companies for corporate reputation that year by multiple sclerosis patient groups familiar with it).

Comparing just the 8 largest pharma companies (‘big pharma’), neurological conditions, 2019 v. 2018

To enable peer-to-peer comparisons of the results, the analyst also recalculates overall rankings for the 12 indicators of corporate reputation for just the 8 largest, multinational, multi-therapy pharma companies included in the neurology analyses in 2019. These ‘big-pharma’ results provide a different perspective on how the largest pharmaceutical companies fare for corporate reputation - enabling true peer-to-peer analyses.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Eli Lilly
  • Lundbeck
  • Novartis
  • Sandoz
  • MORE

1 Executive summary
9 The relationships that neurology patient groups have with pharma, 2019
12 Industry-wide findings, 2019
17 Rankings of the 21 pharma companies, 2019 (v. 2018)among neurology patient groups familiar with the companies
32 Rankings of the 14 pharma companies, 2019 (v. 2018)among neurology patient groups that work with the companies
47 Profiles of the 21 companies, 2019 (v. 2018)

APPENDICES
I What neurology patient groups say on pharma(and how the industry can improve), 2019/2020
II Profiles of respondent neurology patient groups, 2019 As separate supplements:
III The views of 33 epilepsy patient groups, 2019
IV The views of 43 multiple-sclerosis patient groups, 2019

TABLES AND CHARTS
2 The key specialty areas of 2019’s respondent neurology patient groups
3 The corporate reputation of the pharmaceutical industry, 2019 v. 2018 (percentage of five different types of respondent neurology patient groups stating “Excellent” or “Good”)
5 How five different types of neurology patient groups assess the pharmaceutical industry’s ability to perform at various activities of importance to patients, 2019 (percentage of respondent neurology patient groups stating “Excellent” or “Good”)
8 The rankings of 9 ‘big-pharma’ companies at corporate reputation, 2019 v. 2018 (according to respondent neurology patient groups familiar with the companies)
8 The rankings of 8 ‘big-pharma’ companies at corporate reputation, 2019 v. 2018 (according to respondent neurology patient groups that work or partner with the companies)
10 Neurology patient groups: familiarity, and partnerships, with pharma companies, 2019 (according to respondent neurology patient groups)
11 The types of working relationships that respondent neurology patient groups have with pharma companies, 2019
13 The corporate reputation of the pharmaceutical industry, 2019 v. 2018 - compared with that of 8 other healthcare sectors (according to respondent neurology patient groups)
13 The corporate reputation of the pharmaceutical industry, 2013-2019 (according to respondent neurology patient groups)
14 The perceived effectiveness of the pharmaceutical industry at carrying out specific activities, 2019 v. 2018 (according to respondent neurology patient groups)
15 The perceived effectiveness of the pharmaceutical industry at various activities of importance to patient groups, 2019 v. previous years (according to respondent neurology patient groups)
17 Rankings of 21 individual pharma companies, 2019 v. 2018 (according to respondent neurology patient groups familiar with the company)
32 Rankings of 14 individual pharma companies, 2019 v. 2018 (according to respondent neurology patient groups that work or partner with the company)
47 Profiles of the 21 companies, 2019 v. 2018, charts and tables

  • Number of respondent neurology patient groups claiming familiarity with the company, 2019.
  • Number of respondent neurology patient groups saying that they had a working relationship with the company, 2019.
  • Profile of respondent neurology patient groups familiar with the company, 2019: country headquarters; specialties; geographic remit; and types of relationships.
  • Company scores among respondent neurology patient groups familiar with the company, and which work with the company, for each of the 12 indicators of corporate reputation, 2019.
  • Percentage of the respondent neurology patient groups that work with the company, but which also work with other companies, 2019.
  • Overall rankings for the company according to respondent neurology patient groups familiar with the company, 2019 v. 2018.
  • Overall rankings for the company according to respondent neurology patient groups that work with the company, 2019 v. 2018.
  • Company rankings for each of the 12 indicators according to respondent neurology patient groups familiar, or working, with the company, 2019 v. 2018.
  • Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent neurology patient groups familiar with the company, 2019.
  • Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent neurology patient groups that work with the company, 2019.
  • The company’s Patient Corporate Reputation Indexes (PCRIs), 2015-2019 - selected indicators.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Allergan
  • Almirall
  • Bayer
  • Biogen
  • Eisai
  • Eli Lilly
  • Grünenthal
  • Ipsen
  • Lundbeck
  • Merck & Co/MSD
  • Merck KGaA/EMD Serono
  • Novartis
  • Pfizer
  • Roche/Genentech
  • Sandoz
  • Sanofi
  • Servier
  • Takeda/Shire
  • Teva
  • UCB
Note: Product cover images may vary from those shown
Adroll
adroll